Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.
Company Growth (employees)
Type
Public
HQ
Woodcliff Lake, US
Size (employees)
77 (est)+15%
Eagle Pharmaceuticals is headquartered in Woodcliff Lake, US

Key People at Eagle Pharmaceuticals

Scott L. Tarriff

Scott L. Tarriff

President

Eagle Pharmaceuticals Office Locations

Eagle Pharmaceuticals has offices in Woodcliff Lake, Orlando, San Francisco, Chicago and in 15 other locations
Woodcliff Lake, US (HQ)
470 Chestnut Ridge Road
Show all (19)

Eagle Pharmaceuticals Data and Metrics

Eagle Pharmaceuticals Financial Metrics

Eagle Pharmaceuticals's revenue was reported to be $76.8 m in Q1, 2017
USD

Revenue (Q1, 2017)

76.8 m

Gross profit (Q1, 2017)

66 m

Gross profit margin (Q1, 2017), %

86%

Net income (Q1, 2017)

22.9 m

EBIT (Q1, 2017)

32.7 m

Market capitalization (17-Aug-2017)

901.9 m

Cash (31-Mar-2017)

27.7 m
Eagle Pharmaceuticals's current market capitalization is $901.9 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

19.1 m66.2 m189.5 m

Revenue growth, %

247%186%

Cost of goods sold

1.8 m

Gross profit

187.7 m

Gross profit Margin, %

99%

R&D expense

16.8 m27.9 m30.3 m

General and administrative expense

3.7 m

Operating expense total

37.9 m63.7 m136.1 m

EBIT

(18.8 m)2.6 m53.4 m

EBIT margin, %

(98%)4%28%

Interest expense

(1 k)

Interest income

1 k

Pre tax profit

19.3 m2.6 m53.4 m

Income tax expense

1.1 m

Net Income

18 m2.6 m8.1 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

6 m5.7 m29.6 m40.9 m37.8 m76.8 m

Cost of goods sold

3.3 m3.8 m14.6 m11.5 m10.4 m10.8 m

Gross profit

2.7 m2 m15 m29.4 m27.4 m66 m

Gross profit Margin, %

44%35%51%72%72%86%

R&D expense

5.9 m6.9 m6.7 m3.7 m3.2 m7.5 m

General and administrative expense

5.1 m5.5 m11 m12.1 m11.9 m18.6 m

Operating expense total

11 m12.4 m17.6 m15.8 m15.1 m26.1 m

EBIT

(8.3 m)(10.4 m)(897 k)13.7 m12.3 m32.7 m

EBIT margin, %

(139%)(181%)(3%)33%33%43%

Interest expense

(3 k)(5 k)(1 k)(3 k)(3 k)27 k

Interest income

8 k8 k21 k30 k26 k3 k

Pre tax profit

(877 k)13.7 m12.3 m32.7 m

Income tax expense

153 k218 k(19 k)(584 k)(379 k)(9.7 m)

Net Income

(8.2 m)(10.2 m)(896 k)13.1 m12 m22.9 m
USDFY, 2014FY, 2015FY, 2016

Cash

34.9 m79.1 m52.8 m

Accounts Receivable

12 m26.3 m42.2 m

Inventories

1.2 m15 m11.4 m

Current Assets

49.7 m122.3 m109.1 m

PP&E

342 k2.2 m3.3 m

Goodwill

39.7 m

Total Assets

50.1 m124.6 m214.3 m

Accounts Payable

3.5 m3.9 m14.7 m

Current Liabilities

22.2 m34.3 m41 m

Additional Paid-in Capital

137.6 m197.4 m213.9 m

Retained Earnings

(109.7 m)(107.1 m)(25.7 m)

Total Equity

27.9 m90.3 m151.2 m

Financial Leverage

1.8 x1.4 x1.4 x
USDQ1, 2017

Cash

27.7 m

Accounts Receivable

84.7 m

Inventories

3 m

Current Assets

123.6 m

PP&E

3.8 m

Goodwill

39.7 m

Total Assets

224.8 m

Accounts Payable

19 m

Current Liabilities

35.4 m

Additional Paid-in Capital

220.2 m

Retained Earnings

(2.7 m)

Total Equity

166.8 m

Financial Leverage

1.3 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(18 m)2.6 m81.5 m

Depreciation and Amortization

13 k

Accounts Receivable

(2.2 m)(14.3 m)(15.9 m)

Inventories

(1.3 m)(13.8 m)12.3 m

Accounts Payable

2.9 m356 k10.7 m

Cash From Operating Activities

(13.8 m)(9.7 m)53.2 m

Purchases of PP&E

(46 k)(1.9 m)(1.6 m)

Cash From Investing Activities

(20 m)(1.9 m)(45.8 m)

Cash From Financing Activities

46.2 m55.8 m(33.7 m)

Interest Paid

1 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.2 m)(10.2 m)(896 k)13.1 m12 m22.9 m

Accounts Receivable

7.8 m6.7 m10.5 m13 m12.2 m26.5 m52 m47.1 m84.7 m

Inventories

329 k2 m2.3 m7.3 m7.8 m6.4 m7.1 m3 m

Accounts Payable

2.5 m2.5 m5.4 m4.8 m14.1 m10.3 m11.4 m13.1 m19 m
USDY, 2017

Revenue/Employee

1.1 m

Financial Leverage

1.3 x

Eagle Pharmaceuticals Market Value History

Traffic Overview of Eagle Pharmaceuticals

Eagle Pharmaceuticals Online and Social Media Presence

Eagle Pharmaceuticals Company Life and Culture

You may also be interested in